Drug · CHEMBL1672002
THYMOQUINONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. THYMOQUINONE. Drugs and targets, record CHEMBL1672002. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1672002
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases8
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| polycystic ovary syndrome | Phase 2/3 | ClinicalTrials.gov and TTD | 2 | 1 | https://conductscience.org/library/drugs?q=MONDO_0008487 |
| Impaired glucose tolerance | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0040270 |
| Nasal polyposis | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0100582 |
| chronic rhinosinusitis | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006031 |
| gingivitis | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002508 |
| pneumonia | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005249 |
| psoriasis | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005083 |
| psoriasis vulgaris | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_1001494 |
Source Open Targets
Trials7
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04852510 | Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin | Phase 2/3 | 253 | thymoquinone | Its name | ClinicalTrials.gov | |
| NCT05952102 | Nigella Sativa as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia | 104 | thymoquinone | Its name | ClinicalTrials.gov | ||
| NCT05497895 | The Assessment of Clinical Efficacy of Topical Application of 5% Thymoquinone Gel for Gingivitis Patients | Early phase 1 | 70 | thymoquinone | Its name | ClinicalTrials.gov | |
| NCT06070311 | Wound Healing After Endoscopic Sinus Surgery | 50 | thymoquinone | Its name | ClinicalTrials.gov | ||
| NCT07313111 | Thymoquinone as an add-on Therapy for the Management of Patients With Diabetic Peripheral Neuropathy | Phase 4 | 50 | thymoquinone | Its name | ClinicalTrials.gov | |
| NCT04686461 | Effect of Thymoquinone Extracted From Nigella Sativa in the Treatment of Arsenical Keratosis | 34 | thymoquinone | Its name | ClinicalTrials.gov | ||
| NCT06508372 | Topical Thymoquinone in Psoriasis Vulgaris | 30 | thymoquinone | Its name | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1672002
GET https://conductscience.org/api/drugs/v1/CHEMBL1672002/targets